Author

Anthony Romero

Institution: ORIC Pharmaceuticals, Inc. (United States)

Observed institutions: ORIC Pharmaceuticals, Inc. (United States), Universidad Nacional Agraria La Molina

ORCID: 0000-0003-2755-6028

Observed ORCID: 0000-0003-2755-6028

OpenAlex ID: A5080652859

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

2024 · Matthew A. Marx, Aaron C. Burns, et al. · Cancer Research · 2

Genetic diversity in leucine-rich repeats (LRR) of toll-like receptor-2 and -4 genes in three species of South American camelids

2023 · Anthony Romero, Gustavo Gutiérrez, et al. · Small Ruminant Research

Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not

2023 · Siobhan K. McRee, Chelsea Chen, et al. · Cancer Research

Abstract A20: A leukemic model of acquired resistance to BET inhibition reveals a role for CBP/EP300 bromodomains in the regulation of c-MYC expression

2015 · Andrew R. Conery, Richard C. Centore, et al. · Molecular Cancer Research

Works count: 4

Citation count: 2

H-index: 1

I10-index: